ClinicalTrials.gg
RecruitingNCT07531290Updated Oct 13, 2026

PeerScreen Trial - Reducing Screen Media Use in Peer-groups of Young People

An interventional study of Screen media reduction in Mental Health, Social Interaction and Sleep, sponsored by University of Southern Denmark. Recruiting at 1 site in Denmark. Open to participants aged 13 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of Southern Denmark · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 13, 2026Now RecruitingStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
13 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Psychological Well-Being with a site in Denmark — 9 open to participants now, 11 under way, none of them phase 3. Psychological Well-Being · Denmark.

Planned enrollment
15th of 29
240 · median 240
Started
2026
with 3 others
No phase
27 of 34
8 open now
Primary completion
2027-12
later than 9 of 10 live
Registered
32nd of 34
by date
Lead sponsor
5 of 34
University of Southern Denmark

Among the 34 studies in Psychological Well-Being with a site in Denmark, this one is the 15th largest by planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2026, is one of 27 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 32nd registered.

Psychological Well-Being

2,208 studies on the registry are indexed under Psychological Well-Being; 730 are open to participants now.

Browse Psychological Well-Being studies →

Open to participants now

9 of the 34 studies in Psychological Well-Being with a site in Denmark are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 403 Psychological Well-Being studies recruiting now, 223 (55%) set no upper age limit and 155 (38%) stop at 75 or younger; 121 take children under 18; 206 take healthy volunteers.

This study: 13 Years to 24 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Psychological Well-Being with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of the PeerScreen trial is to investigate whether reducing screen media use affects mental health, social interaction, sleep, physical activity, heart rate variability, and behavioral patterns in young people aged 13 to 24 years. The primary question the trial aims to answer is:

Does reducing screen media use over a 4-week period improve mental health among young people?

Researchers will compare a screen media reduction intervention with a control condition in which participants continue their usual screen media use to determine whether reducing screen media use leads to improvements in mental health.

Participants will:

  • be allocated to either a 4-week screen media reduction intervention or a control condition
  • complete a study protocol including questionnaire-based assessments, daily self-reports, and objective monitoring of screen media use, sleep, physical activity, heart rate variability, social interactions, and geolocation
Read the detailed description

The PeerScreen trial is a parallel-group cluster-randomized controlled trial in which peer groups of adolescents and young adults aged 13-24 years are randomized to either a four-week screen media reduction intervention or a control condition. Random allocation of each peer group will occur after completion of a 14-day baseline assessment protocol. Randomization will be conducted using computer-generated block randomization (block sizes 2-6), stratified by mean peer group age (\<18 vs. ≥18 years). In practice, a researcher will log in to an online platform and click "randomize," thereby ensuring allocation concealment.

Participants in the intervention group will be instructed to reduce smartphone use to one hour per day, limit television, computer, and tablet use to 14 hours per week, and keep screen media devices outside the bedroom.

The target sample is 80 peer groups (2-6 peers per group) of adolescents (13-17 years) and young adults (18-24 years), to be recruited via a separate survey study. This survey will be conducted in classes across secondary and higher educational institutions (e.g., secondary schools, high schools, vocational schools, university colleges, and universities) and will describe screen media behaviors among Danish youth. Before administration of the survey, the research team will introduce the PeerScreen trial in each class. At the end of the survey, students will be asked whether they are interested in participating in an experimental study and whether the research team may contact them for follow-up. Written information about the experiment will be provided to interested students during classroom visits and distributed via the school and its online platforms, along with a registration link, after the visits. This procedure will allow students to express interest at a later stage if preferred.

Data collection will combine questionnaires on mental health and well-being, daily reports of mood, sleepiness, and social interactions, and objective monitoring of screen media use, sleep, physical activity, and heart rate variability using a custom application and a wearable device. Bluetooth beacon data will be used to assess social interactions objectively, and geolocation data will be used to provide contextual information about these interactions.

03

Conditions studied

  • Mental Health
  • Social Interaction
  • Sleep
  • Physical Activity
  • Stress

Keywords

  • digital media use
  • screen time
  • adolescent
  • youth
  • young adult
  • mental health
  • social interaction
  • behavioral pattern
  • screen media use
  • heart rate variability
  • sleep
  • physical activity
  • well being
  • peer group
  • interpersonal synchrony
04

Who can participate

Ages eligible
13 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have at least 2 hours/day of self-reported smartphone use during leisure time (data from the survey study)
  • Members of each participant's household must be willing to support the participant in adhering to the prescribed intervention (data from recruitment interview)
  • Participants must have enough discretionary leisure time for possible in-person activities on a weekly basis throughout the study period (verified at the information meeting)

Exclusion criteria

Exclusion Criteria:

  • Participants with no smartphone will be excluded (data from recruitment interview)
  • Participants with no social media profiles will be excluded (data from recruitment interview)
  • Participants who currently participate in other experimental studies will be excluded (data from recruitment interview)
  • Participants who have been hospitalized or prescribed sick leave within the past 3 months due to a mental illness will be excluded (data from recruitment interview)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Screen media reduction

    Peer groups randomized to the intervention will undergo a four-week screen media reduction.

    Behavioral: Screen media reduction

  • No intervention
    Usual screen media use (control)

    Participants allocated to the control group will be asked not to change their use of screen media devices and continue with their usual screen media behaviors. At the randomization meeting, if a peer group is allocated to the control condition, a researcher will explain the importance of the control group for ensuring the validity of the trial, with the aim of keeping these groups motivated and engaged. Participants in the control group will be offered the screen media reduction intervention after completing the long-term follow-up. Accordingly, they will function as a waitlist control group, although no outcome data will be collected during their subsequent intervention period.

Interventions

  • BehavioralScreen media reduction

    Participants will reduce their recreational screen media use across devices. For smartphone use, participants will be asked to reduce their use to a maximum of 1 hour/day. Because social media use will not be permitted on computers or tablets during the intervention, this limit will also encompass participants' social media use. Research staff will help each participant set up smartphone app limits for the ten most used social media and gaming applications, add a widget to their home screen showing the current amount of time they have spent on their phone, and turn off non-essential notifications. For television, computer and tablet use, participants will reduce their use to 14 hours/week (with no specific daily limit), but social media use is not allowed on these devices. We will recommend participants to particularly reduce their solitary screen media use. Participants will be asked to keep their devices outside the bedroom, and they will be provided with a free alarm clock.

06

What researchers measure

Primary outcomes

  1. Change in mental wellbeing on the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)

    Self-reported mental well-being assessed as change in total score on the 14-item Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). Total scores range from 14 to 70 points. Higher scores indicate better mental well-being.

    Time frame: From baseline (day 1) to post-intervention (day 42).

Secondary outcomes

  1. Change in total weekly duration of face-to-face social interaction with peer-group members measured by Bluetooth Low Energy (BLE) beacon proximity events

    Face-to-face social interaction with peer-group members will be assessed as the total duration of proximity events, expressed in minutes per week, using Bluetooth Low Energy (BLE) beacon data collected via the SDU Connect application. The application logs the frequency and duration of proximity events between participants within a predefined distance threshold. The outcome measure is the change in weekly minutes of peer-group proximity from the 14-day baseline period before randomization to the final 21 days of the intervention period.

    Time frame: From the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period

  2. Change in average weekly frequency of self-reported face-to-face social interactions with non-household, non-peer individuals

    Face-to-face social interactions with individuals outside the participant's household and peer group will be assessed using daily self-report collected via the SDU Connect application. These interactions include, for example, family members not living in the household, other friends, and other relations. The outcome measure is the change in the average weekly frequency of self-reported face-to-face social interactions from the 14-day baseline period before randomization to the final 21 days of the intervention period.

    Time frame: From the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period

  3. Change in average nightly total sleep time measured by Garmin Venu 4

    Total sleep time will be assessed using continuous monitoring with the Garmin Venu 4 wearable device. Total sleep time will be derived using the device's sleep algorithm and expressed as average minutes of sleep per night. The outcome measure is the change in average nightly total sleep time from the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

    Time frame: From the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

  4. Change in average daily step count measured by Garmin Venu 4

    Physical activity will be assessed using continuous monitoring with the Garmin Venu 4 wearable device. Physical activity will be expressed as average number of steps per day derived from the device. The outcome measure is the change in average daily step count from the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

    Time frame: From the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period

Other outcomes

  1. Change in average nocturnal heart rate variability measured by Garmin Venu 4 (root mean square of successive differences)

    Heart rate variability during sleep will be assessed using continuous monitoring with the Garmin Venu 4 wearable device. Heart rate variability will be expressed as the root mean square of successive differences (RMSSD) in milliseconds (ms), derived from the device during sleep periods. The outcome measure is the change in average nocturnal RMSSD from the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

    Time frame: From the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

  2. Change in average nightly Garmin Sleep Score measured by Garmin Venu 4

    Sleep quality will be assessed using the Garmin Sleep Score (proprietary overall sleep score) derived from continuous monitoring with the Garmin Venu 4 wearable device. Garmin Sleep Score is a device-derived composite sleep measure ranging from 0 to 100 points, with higher scores indicating better sleep quality. The outcome measure is the change in average nightly Garmin Sleep Score from the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

    Time frame: From the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period

  3. Change in average daily minutes of moderate-to-vigorous physical activity measured by Garmin Venu 4

    Physical activity intensity will be assessed using continuous monitoring with the Garmin Venu 4 wearable device. Moderate-to-vigorous physical activity will be expressed as average minutes per day spent participating in moderate-to-vigorous intensity physical activity, derived from the device. The outcome measure is the change in average daily minutes of moderate-to-vigorous physical activity from the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

    Time frame: From the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

  4. Change in dyadic physiological synchrony in heart rate during peer co-presence measured by Bluetooth Low Energy (BLE) beacons and Garmin Venu 4

    Physiological synchrony will be assessed as similarity in heart rate time series between dyads of peer-group members during periods of co-presence identified by Bluetooth Low Energy (BLE) beacon data. Heart rate will be measured continuously using Garmin Venu 4 wearable devices. Synchrony will be quantified using a Time Warp Edit Distance (TWED)-based dissimilarity measure applied to dyadic heart rate time series during beacon-defined co-presence periods, with lower dissimilarity indicating greater physiological synchrony. The outcome measure is the change in average dyadic heart rate synchrony from the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

    Time frame: From the 14-day baseline period before randomization to the final 21 days of the 4-week intervention period.

  5. Change in self-reported perceived stress score measured by the 4-item Cohen Perceived Stress Scale (PSS-4)

    Perceived stress will be assessed using the 4-item Cohen Perceived Stress Scale (PSS-4). The PSS-4 total score will be used, with higher scores indicating greater perceived stress. Outcome data will be collected at baseline, post-intervention, and long-term follow-up.

    Time frame: Baseline (day 1), post-intervention (day 42), and long-term follow-up (day 70)

  6. Change in self-reported social connectedness score measured by the Friendship Scale

    Social connectedness will be assessed using the Friendship Scale. The outcome measure is the total Friendship Scale score at baseline (Day 1), post-intervention (Day 42), and long-term follow-up (Day 70). Higher scores indicate greater social connectedness.

    Time frame: Baseline (day 1), post-intervention (day 42), and long-term follow-up (day 70)

  7. Change in self-reported loneliness score measured by the UCLA 3-Item Loneliness Scale

    Loneliness will be assessed using the UCLA 3-Item Loneliness Scale. The outcome measure is the total UCLA 3-Item Loneliness Scale score at baseline (Day 1), post-intervention (Day 42), and long-term follow-up (Day 70). Higher scores indicate greater loneliness.

    Time frame: Baseline (day 1), post-intervention (day 42), and long-term follow-up (day 70)

  8. Change in self-reported life satisfaction score measured by Cantril's Ladder

    Life satisfaction will be assessed using Cantril's Ladder. The outcome measure is the self-reported Cantril's Ladder score at baseline (Day 1), post-intervention (Day 42), and long-term follow-up (Day 70). Higher scores indicate greater life satisfaction.

    Time frame: Baseline (day 1), post-intervention (day 42), and long-term follow-up (day 70)

  9. Change in self-reported depressive symptoms score measured by the Mood and Feelings Questionnaire Short Form (MFQ-SF)

    Depressive symptoms will be assessed using the Mood and Feelings Questionnaire Short Form (MFQ-SF). The outcome measure is the total MFQ-SF score at baseline (Day 1), post-intervention (Day 42), and long-term follow-up (Day 70). Higher scores indicate greater depressive symptom severity.

    Time frame: Baseline (day 1), post-intervention (day 42), and long-term follow-up (day 70)

  10. Change in self-reported anxiety symptoms score measured by the Generalized Anxiety Disorder 2-Item scale (GAD-2)

    Anxiety symptoms will be assessed using the Generalized Anxiety Disorder 2-Item scale (GAD-2). The outcome measure is the total GAD-2 score at baseline (Day 1), post-intervention (Day 42), and long-term follow-up (Day 70). Higher scores indicate greater anxiety symptom severity.

    Time frame: Baseline (day 1), post-intervention (day 42), and long-term follow-up (day 70)

  11. Change in self-reported sleep disturbance score measured by the PROMIS Pediatric Sleep Disturbance Short Form 8a

    Sleep disturbance will be assessed using the PROMIS Pediatric Sleep Disturbance Short Form 8a. The outcome measure is the total PROMIS Pediatric Sleep Disturbance Short Form 8a score at baseline (Day 1), post-intervention (Day 42), and long-term follow-up (Day 70). Higher scores indicate greater sleep disturbance.

    Time frame: Baseline (day 1), post-intervention (day 42), and long-term follow-up (day 70)

  12. Change in self-reported problematic smartphone use score measured by the Smartphone Addiction Scale-Short Version (SAS-SV)

    Problematic smartphone use will be assessed using the Smartphone Addiction Scale-Short Version (SAS-SV). The outcome measure is the total SAS-SV score at baseline (Day 1), post-intervention (Day 42), and long-term follow-up (Day 70). Higher scores indicate greater problematic smartphone use.

    Time frame: Baseline (day 1), post-intervention (day 42), and long-term follow-up (day 70)

  13. Change in daily self-reported mood score measured by a visual analogue scale (VAS)

    Mood will be assessed using a self-reported visual analogue scale (VAS) administered daily during the 14-day baseline period before randomization and daily during the 42-day intervention period. The outcome measure is the change in daily mood scores from the 14-day baseline period before randomization to the final 21 days of the intervention period, with higher scores indicating more positive mood.

    Time frame: Daily during the 14-day baseline period before randomization and daily during the 42-day intervention period.

  14. Change in daily self-reported stress score measured by a visual analogue scale (VAS)

    Stress will be assessed using a self-reported visual analogue scale (VAS) administered daily during the 14-day baseline period before randomization and daily during the 42-day intervention period. The outcome measure is the change in daily stress scores from the 14-day baseline period before randomization to the final 21 days of the intervention period, with higher scores indicating greater perceived stress.

    Time frame: Daily during the 14-day baseline period before randomization and daily during the 42-day intervention period.

  15. Change in daily self-reported sleepiness score measured by a visual analogue scale (VAS)

    Sleepiness will be assessed using a self-reported visual analogue scale (VAS) administered daily during the 14-day baseline period before randomization and daily during the 42-day intervention period. The outcome measure is the change in daily sleepiness scores from the 14-day baseline period before randomization to the final 21 days of the intervention period, with higher scores indicating greater sleepiness.

    Time frame: Daily during the 14-day baseline period before randomization and daily during the 42-day intervention period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Schmidt-Persson J, Gejl AK, Philipsen KB, Johansen MS, Mathiesen J, Taylor R, Flensborg-Madsen T, Kristensen PL, Grontved A. Effects of reducing screen media use on mental health, sleep, physical activity, heart rate variability, and behavioral patterns in peergroups of young people: a study protocol for a cluster-randomized controlled trial. BMC Psychol. 2026 May 28;14(1):1098. doi: 10.1186/s40359-026-04827-5. PubMed 42204593 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant data will be shared with other researchers for research purposes only and only upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Access criteria: Researchers will be asked to write a proposal described how data will be used. They will be able to access data by writing an email to the corresponding author.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

Of 1,274 non-industry interventional studies with no phase under Psychological Well-Being, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 19 months is above that.

Counting every sponsor, half of 1,317 studies reached it within 16 months; a quarter within 7 and three quarters within 34.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → May 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 15, 2026
StartActual
May 4, 2026was Apr 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added — first site in Denmark
Show site
  • University of Southern Denmark · Odense, Denmark
Oct 13, 2026
Start date
Apr 15, 2026→May 4, 2026 (actual)
Oct 13, 2026
Documents
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    Documents Study protocol ↗ posted
    1 site added — first site in Denmark
    Show site
    • University of Southern Denmark · Odense, Denmark
    Start date Apr 15, 2026→May 4, 2026 (now actual)
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07531290
Responsible party
Anders Groentved (Professor, University of Southern Denmark) — Principal investigator
First posted
Apr 15, 2026
Start date
May 4, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Jesper Schmidt-Persson, PhD
Contact
jespedersen@health.sdu.dk
+4565502054
Anne K Gejl, PhD
Contact
akgejl@health.sdu.dk
+4565507908
Anders Grøntved, PhD
principal investigator · University of Southern Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion